HK1084676A1 - Antibody anti human nogo a and its pharmaceutical use - Google Patents

Antibody anti human nogo a and its pharmaceutical use

Info

Publication number
HK1084676A1
HK1084676A1 HK06102543.2A HK06102543A HK1084676A1 HK 1084676 A1 HK1084676 A1 HK 1084676A1 HK 06102543 A HK06102543 A HK 06102543A HK 1084676 A1 HK1084676 A1 HK 1084676A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical use
human
anti human
antibody anti
binding molecule
Prior art date
Application number
HK06102543.2A
Other languages
English (en)
Inventor
Carmen Barske
Thomas Oertle
Martin E Schwab
Mauro Zurini
Anis Khusro Mir
Lisa Schnell
Alessandra Vitaliti
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of HK1084676A1 publication Critical patent/HK1084676A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK06102543.2A 2002-12-10 2006-02-24 Antibody anti human nogo a and its pharmaceutical use HK1084676A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound
PCT/EP2003/013960 WO2004052932A2 (en) 2002-12-10 2003-12-09 Antibody (“11c7”) anti nogo a and its pharmaceutical use

Publications (1)

Publication Number Publication Date
HK1084676A1 true HK1084676A1 (en) 2006-08-04

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102543.2A HK1084676A1 (en) 2002-12-10 2006-02-24 Antibody anti human nogo a and its pharmaceutical use

Country Status (25)

Country Link
US (2) US7785593B2 (xx)
EP (1) EP1572745B1 (xx)
JP (1) JP4504200B2 (xx)
KR (1) KR101215801B1 (xx)
CN (1) CN100384877C (xx)
AT (1) ATE475671T1 (xx)
AU (1) AU2003289998B2 (xx)
BR (1) BR0317161A (xx)
CA (1) CA2509068C (xx)
CY (1) CY1110848T1 (xx)
DE (1) DE60333585D1 (xx)
DK (1) DK1572745T3 (xx)
EC (1) ECSP055849A (xx)
ES (1) ES2349293T3 (xx)
GB (1) GB0228832D0 (xx)
HK (1) HK1084676A1 (xx)
IL (1) IL169018A (xx)
MX (1) MXPA05006265A (xx)
NO (1) NO20053304L (xx)
PL (1) PL210720B1 (xx)
PT (1) PT1572745E (xx)
RU (1) RU2350623C2 (xx)
SI (1) SI1572745T1 (xx)
WO (1) WO2004052932A2 (xx)
ZA (1) ZA200504522B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
PT1711530E (pt) * 2003-12-22 2009-10-22 Glaxo Group Ltd Imunoglobulinas neutralizantes de nogo-a para o tratamento de doenças neurológicas
KR20080030960A (ko) * 2005-07-05 2008-04-07 글락소 그룹 리미티드 Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
NZ584911A (en) * 2007-11-02 2011-08-26 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
EP2870177A1 (en) 2012-07-05 2015-05-13 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CA2915250A1 (en) * 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
IL296874A (en) 2016-03-01 2022-11-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific for the human poliovirus receptor
AU2020370751A1 (en) 2019-10-24 2022-06-09 Novago Therapeutics Ag Novel anti-Nogo-A antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
JP3854306B2 (ja) * 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
EP1098972B1 (en) 1998-07-22 2010-09-29 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding cdna
SK287323B6 (sk) 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GEP20063830B (en) * 2000-01-12 2006-05-25 Univ Yale Nogo Receptor-Mediated Blockade of Axonal Growth
DE60230736D1 (de) 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
EP2990394A1 (en) * 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
PT1711530E (pt) * 2003-12-22 2009-10-22 Glaxo Group Ltd Imunoglobulinas neutralizantes de nogo-a para o tratamento de doenças neurológicas
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
KR20050095768A (ko) 2005-09-30
RU2350623C2 (ru) 2009-03-27
DK1572745T3 (da) 2010-10-25
RU2005121669A (ru) 2007-01-20
GB0228832D0 (en) 2003-01-15
MXPA05006265A (es) 2005-12-05
WO2004052932A3 (en) 2004-10-21
CA2509068A1 (en) 2004-06-24
NO20053304L (no) 2005-09-07
US20060183678A1 (en) 2006-08-17
DE60333585D1 (de) 2010-09-09
ES2349293T3 (es) 2010-12-29
PL377506A1 (pl) 2006-02-06
JP4504200B2 (ja) 2010-07-14
US7785593B2 (en) 2010-08-31
EP1572745A2 (en) 2005-09-14
IL169018A (en) 2012-07-31
US8535666B2 (en) 2013-09-17
KR101215801B1 (ko) 2012-12-26
CN1747971A (zh) 2006-03-15
ZA200504522B (en) 2006-03-29
WO2004052932A2 (en) 2004-06-24
CA2509068C (en) 2012-02-07
ATE475671T1 (de) 2010-08-15
PT1572745E (pt) 2010-10-21
NO20053304D0 (no) 2005-07-06
CY1110848T1 (el) 2015-06-10
CN100384877C (zh) 2008-04-30
BR0317161A (pt) 2005-11-01
JP2006523087A (ja) 2006-10-12
AU2003289998A1 (en) 2004-06-30
SI1572745T1 (sl) 2010-12-31
US20110059110A1 (en) 2011-03-10
ECSP055849A (es) 2005-09-20
AU2003289998B2 (en) 2008-02-14
EP1572745B1 (en) 2010-07-28
PL210720B1 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
HK1084676A1 (en) Antibody anti human nogo a and its pharmaceutical use
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
WO2006087637A3 (en) Anti her2/neu antibody
MX2010004915A (es) Anticuerpos para gdf8 asi como sus usos.
CA2501984A1 (en) Erythropoietin receptor binding antibodies
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
WO2003034903A3 (en) Psma antibodies and protein multimers
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
WO2007039818A3 (en) Antigen binding molecules having modified fc regions and altered binding to fc receptors
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
IL168058A (en) Antibody preferentially linked to cell Ca125 / 0722p relative to ca125 / 0722p deciduous cell, the pharmaceutical composition containing it and its use in the preparation of a drug
MX2008009886A (es) Anticuerpos que enlazan par-2.
TW200635946A (en) Binding proteins specific for human matriptase
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
TNSN06085A1 (en) Nogo-a binding with enhanced affinity and pharmaceutical use thereof
ATE312921T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
Cozma Determination of Primary Structure and Affinity Characterization of Naturally Occurring β-Amyloid Autoantibodies
WO2022223970A3 (en) Method and composition
MX2024003139A (es) Multabody dirigido a dr5 para el tratamiento del cancer.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151209